专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR20200130224A 방출제어된 위체류 서방성 제제 审中-公开
公开(公告)号：KR20200130224A
公开(公告)日：2020-11-18
申请号：KR20200151205
申请日：2020-11-12
申请人： DONG A ST CO LTD
发明人： KIM SOON HOE , SON MI WON , JANG SUN WOO , KIM JEONG SOO , CHA KWANG HO , KANG SEUNG YEOB , JUNG SANG WON
IPC分类号： A61K9/00 , A61K9/20 , A61K36/282 , A61K47/30
摘要： 본발명은약물의위 체류및 방출조절을위한위체류서방성제제에관한것으로서, 구체적으로는복용즉시위 내에부유/체류하면서약물의방출을제어할수 있는위체류서방성제제에관한것이다. 본발명은위 내 pH 에영향을받지않고위액과접촉즉시부유하며, 방출제어제함량 %를조절함에따라약물방출을손쉽게제어할수 있다. 따라서, 본발명은저산증환자, 식전복용시, 위내 pH 상승또는위액양의부족으로인한경우등 식이에따라위액의 pH 및위액량이크게달라지는환경에서도경구투여시, 약물이소장으로이행가능성없이위에서체류하며장시간동안활성성분을지속적으로방출시킬수 있다.

2. 发明公开

KR20180071987A 청대 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 약학적 조성물 审中-公开
公开(公告)号：KR20180071987A
公开(公告)日：2018-06-28
申请号：KR20170176160
申请日：2017-12-20
申请人： SEOUL NATIONAL UNIV HOSPITAL , DONG A ST CO LTD
发明人： CHO YOUNG WOONG , SON MI WON , CHOI SANG ZIN , CHOI SONG HYEN , JEONG JIN SEOK , SONG IN SUNG , KIM NAYOUNG
IPC分类号： A61K36/70 , A23L33/105
CPC分类号： A23L33/105 , A61K36/70
摘要： 본발명은청대추출물또는이의분획물을유효성분으로포함하는염증성장질환의예방또는치료용약학적조성물에관한것이다. 본발명에따른청대추출물또는이의분획물은염증활성지표인자들의활성및 발현을감소시키고, 염증성장질환의질병활성도를개선시키는효과를나타내어, 염증성장질환의예방및 치료제로유용하게사용될수 있다.

3. 发明公开

KR20200138055A SGLT-2 억제제인 신규 엠파글리플로진 유도체 审中-公开
公开(公告)号：KR20200138055A
公开(公告)日：2020-12-09
申请号：KR20200064423
申请日：2020-05-28
申请人： DONG A ST CO LTD
发明人： SUNG SI YOUNG , SON BYOUNG HWA , ULLAPU PUNNA REDDY , MOK HUI YEON , LIM HONG GYU , KIM JEONG SOO
IPC分类号： C07H7/06
摘要： 본발명은신규의엠파글리플로진유도체에관한것으로서, 상기신규화합물은 SGLT-2 억제제로유용하다. 또한, 본발명에의한신규의엠파글리플로진유도체는 SGLT-2 억제제로개발된약물인엠파글리플로진보다상대적으로융점이높고흡습성이낮으며우수한보존안정성을보여제제화에매우적합하다.

4. 发明专利

JP2020502278A 青黛抽出物又はその分画物を有効成分として含む炎症性腸疾患の予防又は治療のための医薬組成物审中-公开
公开(公告)号：JP2020502278A
公开(公告)日：2020-01-23
申请号：JP2019554467
申请日：2017-12-20
申请人：ソウルナショナルユニバーシティホスピタル , SEOUL NATIONAL UNIVERSITY HOSPITAL , ドンエーエスティカンパニーリミテッド , DONG−A ST Co.,LTD.
发明人：チョ、ヤンウング , ソン、ミウォン , チョイ、サンジン , チョイ、ソンヒエン , ジェオン、ジンソク , ソング、インサン , キム、ナヨン
IPC分类号： A61K36/70 , A61P1/04 , A61K36/195
摘要：本発明は、青黛抽出物又はその分画物を有効成分として含む炎症性腸疾患の予防又は治療のための医薬組成物に関する。本発明による青黛抽出物又はその分画物は、炎症活性指標因子の活性及び発現を減少させ、炎症性腸疾患の疾患活動性を改善する効果があるため、炎症性腸疾患の予防及び治療薬として有用である。

7. 发明申请

WO2023033557A1 PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING MEMANTINE ENANTHATE 审中-公开
公开(公告)号：WO2023033557A1
公开(公告)日：2023-03-09
申请号：PCT/KR2022/013084
申请日：2022-09-01
申请人： DONG-A ST CO., LTD.
发明人： JANG, Sun-Woo , SHIN, Chang-Yell , KIM, Hae-Sun , HYUN, Sang-Min , KIM, Yong-Jik , SHIN, Chang-Yong , KIM, Jae-Han
IPC分类号： A61K9/70 , A61K47/14 , A61K31/13 , A61P25/28
摘要： The present invention provides a percutaneous absorption preparation for the treatment of dementia, comprising a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer comprises memantine enanthate, a solubilizer, and a pressure-sensitive adhesive. The percutaneous absorption preparation for the treatment of dementia according to the present invention does not form crystal precipitation, shows high skin permeability, allows easy clinical control of the usable patch area, and allows control of the absorption rate by adjusting the rate of release, thus minimizing skin irritation, and provides an economic benefit of minimal waste of the drug while also preventing overdose of the drug.

8. 发明申请

WO2021101346A1 ANTI-ROR1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2021101346A1
公开(公告)日：2021-05-27
申请号：PCT/KR2020/016567
申请日：2020-11-23
申请人： DONG-A ST CO., LTD. , ABL BIO INC.
发明人： CHO, Jongho , DOH, Hyounmie , LEE, Dongsop , KO, Eun , LEE, Yangsoon , PARK, Kyeongsu , CHUNG, Hyejin , PARK, Kyungjin , JUNG, Ui-Jung , JEON, Jaehyoung , KIM, Youngkwang , KIM, Juhee , SON, Wonjun
IPC分类号： C07K16/28 , A61P35/00 , A61P31/00 , A61P37/00 , A61K39/00
摘要： The present disclosure provides an anti-ROR1/anti-4-1BB bispecific antibody capable of simultaneously binding to ROR1 and 4-1BB with high affinity, and capable of enhancing immune response and/or treating tumor (cancer) in a mammal.

9. 发明申请

WO2016099056A8 COMPOSITION CONTAINING PORIA COCOS BARK EXTRACT FOR PREVENTING, IMPROVING OR TREATING NEURODEGENERATIVE DISORDERS 审中-公开
公开(公告)号：WO2016099056A8
公开(公告)日：2017-06-29
申请号：PCT/KR2015013136
申请日：2015-12-03
申请人： DONG-A ST CO LTD
发明人： CHOI SANG ZIN , SOHN MI WON , GO HYO SANG , RYU JA YOUNG , JEONG JIN SEOK , CHOI SONG HYEN , KIM EUN JIN , CHO YOUNG WOONG , KIM SO YOUNG
IPC分类号： A61K36/076 , A61P25/00 , A61P25/16 , A61P25/28
CPC分类号： A61K36/076
摘要： The present invention relates to a pharmaceutical composition containing a Poria cocos bark extract as an effective ingredient for preventing or treating neurodegenerative disorders, and to a food composition for preventing or improving neurodegenerative disorders. The Poria cocos bark extract contained as an effective ingredient in the composition of the present invention has a function of protecting neurons by generation of beta-amyloid, inhibition of tau phosphorylation, and promotion of NFG generation, and a function of improving memory by protection of neurons and inhibition of acetylcholinesterase, and thus can be usefully used in a pharmaceutical composition for preventing or treating neurodegenerative disorders or a functional food for said purpose.

10. 发明申请

WO2014200211A1 LIQUID PHARMACEUTICAL COMPOSITION CONTAINING PIROXICAM AND HYALURONIC ACID FOR THE TREATMENT OF OSTEOARTHRITIS 审中-公开
标题翻译：含有PIROXICAM和HYALURONIC酸的液体药物组合物用于治疗OSTEOARTHRITIS
公开(公告)号：WO2014200211A1
公开(公告)日：2014-12-18
申请号：PCT/KR2014/004745
申请日：2014-05-27
申请人： DONG-A ST CO., LTD
发明人： KIM, Soon-Hoe , SON, Mi-Won , JANG, Sun-Woo , PARK, Chan-Woong , MA, Kyung-Wan , JUNG, Sang-Won
IPC分类号： A61K31/54 , A61K31/728 , A61P19/02 , A61P19/00
CPC分类号： A61K31/728 , A61K9/0019 , A61K31/5415 , A61K47/02 , A61K2300/00
摘要： The present invention relates to the pharmaceutical composition for the treatment of osteoarthritis comprising piroxicam or pharmaceutically acceptable salt thereof and hyaluronic acid or pharmaceutically acceptable salt thereof at a specific ratio that generates synergistic effect on both anti-inflammatory and analgesic effects simultaneously. The present invention provides a pharmaceutical composition for the treatment of osteoarthritis comprising 0.25-10.0 wt% of piroxicam or its pharmaceutically acceptable salt and 0.5-5.0 wt% of hyaluronic acid or its pharmaceutically acceptable salt, where the weight ratio between piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt is between 1:1 and 1:3. The liquid pharmaceutical composition according to the present invention has an outstanding therapeutic effect simultaneously on both inflammation and pain, thus providing an injectable formulation for intra-articular injection with synergistic effect on the treatment of osteoarthritis.
摘要翻译：本发明涉及用于治疗骨关节炎的药物组合物，其包含吡罗昔康或其药学上可接受的盐和透明质酸或其药学上可接受的盐，其特定比例同时产生对抗炎和镇痛作用的协同作用。本发明提供了用于治疗骨关节炎的药物组合物，其包含0.25-10.0重量％的吡罗昔康或其药学上可接受的盐和0.5-5.0重量％的透明质酸或其药学上可接受的盐，其中，炎痛喜酸或其药学上可接受的盐的重量比盐和透明质酸或其药学上可接受的盐在1:1至1:3之间。根据本发明的液体药物组合物在炎症和疼痛方面同时具有突出的治疗效果，因此提供关节内注射的可注射制剂，对治疗骨关节炎具有协同作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式